Matches in Wikidata for { <http://www.wikidata.org/entity/Q106637899> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q106637899 description "clinical trial" @default.
- Q106637899 description "ensayo clínico" @default.
- Q106637899 description "ensayu clínicu" @default.
- Q106637899 description "klinisch onderzoek" @default.
- Q106637899 description "клінічне випробування" @default.
- Q106637899 description "临床试验" @default.
- Q106637899 name "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 name "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 type Item @default.
- Q106637899 label "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 label "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 prefLabel "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 prefLabel "A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer" @default.
- Q106637899 P1132 Q106637899-DA670090-F0F7-4D04-853C-3F57414117EF @default.
- Q106637899 P1476 Q106637899-E903628E-1781-458C-BF4F-1C7A80AD52BB @default.
- Q106637899 P2899 Q106637899-126AF234-0C49-4B0A-8CDE-3FFFABAC193B @default.
- Q106637899 P3098 Q106637899-D528C293-685E-4385-8688-B974EBF1F206 @default.
- Q106637899 P31 Q106637899-610C160D-4311-4261-B72D-633122AD8137 @default.
- Q106637899 P580 Q106637899-ECA34C64-EE37-48D4-8BF2-549B6300A31B @default.
- Q106637899 P582 Q106637899-668C2C7C-0C0A-48CD-B1CA-6DDAF03C96E8 @default.
- Q106637899 P6099 Q106637899-04B162FA-4E5B-4BC3-BBE9-F53C388D0946 @default.
- Q106637899 P6099 Q106637899-9232164D-A088-4F5C-BBA6-30948B8EC69E @default.
- Q106637899 P8005 Q106637899-51F31159-3EB5-4BF3-80AB-FD652F1FA9B6 @default.
- Q106637899 P8363 Q106637899-E8B72EA8-DE5D-466F-9D59-6F9ACDA2AFF9 @default.
- Q106637899 P1132 "+79" @default.
- Q106637899 P1476 "A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)" @default.
- Q106637899 P2899 "+18" @default.
- Q106637899 P3098 "NCT04813107" @default.
- Q106637899 P31 Q30612 @default.
- Q106637899 P580 "2021-09-01T00:00:00Z" @default.
- Q106637899 P582 "2023-11-01T00:00:00Z" @default.
- Q106637899 P6099 Q42824440 @default.
- Q106637899 P6099 Q5452194 @default.
- Q106637899 P8005 Q76649614 @default.
- Q106637899 P8363 Q78089383 @default.